Teva Octreotide Acetate Injection Recalled for Sterility Assurance Failure
Teva Pharmaceuticals is recalling Octreotide Acetate Injection 1000 mcg/5mL vials nationwide due to lack of assurance of sterility. The recall affects 16,644 vials distributed nationally.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable drug product. Lack of sterility assurance in multi-dose injectable medications poses a serious risk of infection if the product is administered, meeting the Severe classification criteria for Class II recalls involving injectable pharmaceuticals.
Plain-English summary
Teva Pharmaceuticals USA is recalling Octreotide Acetate Injection 1000 mcg/5mL, 5 mL multi-dose vials (NDC 0703-3333-01) due to lack of assurance of sterility. The affected lot is #31329150B with an expiration date of 06/2022. Approximately 16,644 vials were distributed nationwide, including Puerto Rico.
Octreotide acetate is a prescription medication used to treat certain medical conditions. A failure in sterility assurance means that the manufacturer cannot guarantee the product is free from microbial contamination, which could pose a risk to patients who receive the injection.
Patients currently taking this medication should contact their healthcare provider or pharmacist immediately to determine if they have received product from the recalled lot. Patients should not stop taking their medication without consulting their healthcare provider. Healthcare providers and patients with questions should contact Teva Pharmaceuticals USA or consult with their pharmacy regarding replacement product or alternative treatments.
The recalled product
- Product
- Octreotide Acetate Injection 1000 mcg/5mL, 5 mL multi-dose vial, Rx only, Teva Pharmaceuticals USA. Inc. North Wales, PA 19454, NDC 0703-3333-01
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Injectable / Octreotide
- Hazard
- sterility-failure
- microbial-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 31329150B
- exp. date 06/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27